{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:22:30Z","timestamp":1771654950307,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,30]]},"DOI":"10.7759\/cureus.14769","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T11:14:53Z","timestamp":1619781293000},"source":"Crossref","is-referenced-by-count":3,"title":["Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa"],"prefix":"10.7759","author":[{"given":"Amna","family":"Al-Tkrit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Obada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Muqeet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05189.x","article-title":"Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy","volume":"36","author":"Bessissow T","year":"2012","unstructured":"Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012, 36:312-23. 10.1111\/j.1365-2036.2012.05189.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1697930","article-title":"Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics","volume":"46","author":"Danese E","year":"2020","unstructured":"Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost. 2020, 46:264-7. 10.1055\/s-0039-1697930","journal-title":"Semin Thromb Hemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12052","article-title":"A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia","volume":"11","author":"Arnold DM","year":"2013","unstructured":"Arnold DM, Kukaswadia S, Nazi I, et al.. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost. 2013, 11:169-76. 10.1111\/jth.12052","journal-title":"J Thromb Haemost"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427150-00007","article-title":"Drug-induced immune thrombocytopenia","volume":"27","author":"van den Bemt PM","year":"2004","unstructured":"van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf. 2004, 27:1243-52. 10.2165\/00002018-200427150-00007","journal-title":"Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200301","article-title":"Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events","volume":"22","author":"Murdaca G","year":"2009","unstructured":"Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009, 22:557-65. 10.1177\/039463200902200301","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s15007-020-2550-1","article-title":"Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events","volume":"29","author":"G\u00fclsen A","year":"2020","unstructured":"G\u00fclsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J. 2020, 29:32-61. 10.1007\/s15007-020-2550-1","journal-title":"Allergo J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0220-6","article-title":"Adalimumab: a review in hidradenitis suppurativa","volume":"17","author":"Kim ES","year":"2016","unstructured":"Kim ES, Garnock-Jones KP, Keam SJ. Adalimumab: a review in hidradenitis suppurativa. Am J Clin Dermatol. 2016, 17:545-52. 10.1007\/s40257-016-0220-6","journal-title":"Am J Clin Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2018.7859","article-title":"Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: real life data","volume":"10","author":"Kyriakou A","year":"2018","unstructured":"Kyriakou A, Trigoni A, Galanis N, Sotiriadis D, Patsatsi A. Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: real life data. Dermatol Reports. 2018, 10:7859. 10.4081\/dr.2018.7859","journal-title":"Dermatol Reports"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072212","article-title":"Pathophysiology and diagnosis of drug-induced immune thrombocytopenia","volume":"9","author":"Vayne C","year":"2020","unstructured":"Vayne C, Gu\u00e9ry EA, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med. 2020, 9:2212. 10.3390\/jcm9072212","journal-title":"J Clin Med"},{"key":"ref10","article-title":"Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors","volume":"10","author":"Chen M","year":"2011","unstructured":"Chen M, Holland MJ, Mir MR, et al.. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors. J Drugs Dermatol. 2011, 10:280-4.","journal-title":"J Drugs Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.001","article-title":"Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis","volume":"60","author":"Brunasso AM","year":"2009","unstructured":"Brunasso AM, Massone C. Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. J Am Acad Dermatol. 2009, 60:781-5. 10.1016\/j.jaad.2008.12.001","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.23937\/2469-5696\/1410020","article-title":"Chronic use of adalimumab as potential cause of severe thrombocytopenia in psoriatic arthritis patient: the need for regular monitoring of cytopenias","volume":"3","author":"Pereira VC","year":"2016","unstructured":"Pereira VC, Costa KH, de Oliveira LR. Chronic use of adalimumab as potential cause of severe thrombocytopenia in psoriatic arthritis patient: the need for regular monitoring of cytopenias. Int J Blood Res Disord. 2016, 3:020. 10.23937\/2469-5696\/1410020","journal-title":"Int J Blood Res Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.04.001","article-title":"Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease","volume":"6","author":"Casanova MJ","year":"2012","unstructured":"Casanova MJ, Chaparro M, Mart\u00ednez S, Vicu\u00f1a I, Gisbert JP. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease. J Crohns Colitis. 2012, 6:1034-7. 10.1016\/j.crohns.2012.04.001","journal-title":"J Crohns Colitis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel204","article-title":"TNF\u03b1 blocker-induced thrombocytopenia","volume":"45","author":"Pathare SK","year":"2006","unstructured":"Pathare SK, Heycock C, Hamilton J. TNF\u03b1 blocker-induced thrombocytopenia. Rheumatology (Oxford). 2006, 45:1313-4. 10.1093\/rheumatology\/kel204","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.artd.2020.03.006","article-title":"Drug-induced thrombocytopenia secondary to commonly used antibiotics in total joint arthroplasty","volume":"6","author":"Savage-Elliott I","year":"2020","unstructured":"Savage-Elliott I, Wu VJ, Sanchez FL. Drug-induced thrombocytopenia secondary to commonly used antibiotics in total joint arthroplasty. Arthroplast Today. 2020, 6:137-40. 10.1016\/j.artd.2020.03.006","journal-title":"Arthroplast Today"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312467400","article-title":"Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans","volume":"41","author":"Everds NE","year":"2013","unstructured":"Everds NE, Tarrant JM. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicol Pathol. 2013, 41:280-302. 10.1177\/0192623312467400","journal-title":"Toxicol Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/57817-adalimumab-induced-thrombocytopenia-in-a-patient-with-hidradenitis-suppurativa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:03Z","timestamp":1707507003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/57817-adalimumab-induced-thrombocytopenia-in-a-patient-with-hidradenitis-suppurativa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.14769","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,30]]}}}